Arrhythmias & electrophysiology
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Pooled result · AF occurrenceResult — go to the resultRelative risk 0.90 95% CI 0.80–1.01Authors' conclusion
For patients with cardiometabolic diseases or risk factors, SGLT2 inhibitors did not decrease the risk of AF occurrence, regardless of follow-up duration, type or dose of the drug, or the patient population.
Study context
- Population
- Patients with DM, HF, CKD or cardiometabolic risk factors
- Participants
- 101,100 patients46 RCTs
- Comparison
- SGLT2 inhibitors vs placebo
- Outcome
- AF occurrence
Methodological detailsplacebo-controlled trials
- Placebo-controlled trials
Pooled result
As reported in the abstract
Relative risk
0.90
95% CI 0.80–1.01
SGLT2 inhibitors vs Placebo
RR 0.90 (95% CI 0.80–1.01)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| AF occurrence, by SGLT2 inhibitorCanagliflozin vs Placebo | 0.82 (0.60–1.12) | |
| AF occurrence, by SGLT2 inhibitorDapagliflozin vs Placebo | 0.87 (0.73–1.03) | |
| AF occurrence, by SGLT2 inhibitorEmpagliflozin vs Placebo | 0.97 (0.78–1.22) | |
| AF occurrence, by SGLT2 inhibitorSotagliflozin vs Placebo | 0.99 (0.66–1.50) | |
| AF occurrence, by SGLT2 inhibitorErtugliflozin vs Placebo | 0.87 (0.58–1.29) | |
| 0.512Relative risk (log scale) |
Atrial fibrillation (AF) occurrence, by dose and in DM, HF and CKD subgroups
- Similar results across doses; no association in patients with DM, HF or CKD
Original publication
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. Published 15 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →